Syndromic microphthalmia
MONDO:0016073A microphthalmia that is part of a larger syndrome.
Also known as: microphthalmia, syndromic, syndrome associated with microphthalmia, syndromic microphthalmia
11 clinical trials for this condition and its sub-types, 0 tagged with Syndromic microphthalmia itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Sub-types of Syndromic microphthalmia
-
Matthew-Wood syndrome 5 trials
-
COFS syndrome 1 trial
5 sub-types
- Cerebrooculofacioskeletal syndrome 1 0 trials
- Cerebrooculofacioskeletal syndrome 2 0 trials
- Cerebrooculofacioskeletal syndrome 3 0 trials
- Cerebrooculofacioskeletal syndrome 4 0 trials
- Xeroderma pigmentosum group G 0 trials
-
MMEP syndrome 1 trial
-
Behrens Baumann dust syndrome 0 trials
-
RAB18 deficiency 0 trials
2 sub-types
- Martsolf syndrome 0 trials Sub-types →
- Warburg micro syndrome 0 trials Sub-types →
-
Microphthalmia, Lenz type 0 trials
-
Microphthalmia, syndromic 1 0 trials
-
Microphthalmia, syndromic 11 0 trials
-
Microphthalmia, syndromic 12 0 trials
-
Microphthalmia, syndromic 2 0 trials
-
Oculoauricular syndrome 0 trials
-
Syndromic microphthalmia type 5 0 trials
Most studied deeper sub-types
-
Double antibody attack: new hope for tough pancreatic cancer?
Disease control OngoingThis phase 2 trial tests whether adding a new antibody called HLX22 to standard treatment (trastuzumab plus chemotherapy) can shrink tumors and improve survival in people with HER2-positive pancreatic cancer that has spread. The study enrolls 45 adults who have not had prior trea…
Phase 2 • Sponsor: Shanghai Zhongshan Hospital • Aim: Disease control
Last updated Jun 27, 2026 08:02 UTC
-
Experimental drug offered to cancer patients with severe wasting
Symptom relief Expanded access (ended)This expanded access program gives seriously ill adults with advanced pancreatic cancer and cachexia (severe weight loss and muscle wasting) access to the experimental drug mifomelatide. Patients receive a daily injection for up to 13 weeks. The goal is to provide a potential tre…
Sponsor: Endevica Bio • Aim: Symptom relief
Last updated Jun 27, 2026 09:05 UTC
-
Which reversal drug causes fewer bathroom problems after surgery?
Knowledge-focused OngoingThis study reviewed records of 70,000 adults who had non-urinary surgery under general anesthesia. It compared two drugs used to reverse muscle relaxants: sugammadex and neostigmine (given with atropine or glycopyrrolate). The goal was to see which drug is linked to fewer cases o…
Sponsor: Beth Israel Deaconess Medical Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:13 UTC